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Abstract 
This work addresses the integrated optimisation of upstream and downstream processing strategies 
of a monoclonal antibody (mAb) under uncertainty. In the upstream processing (USP), the 
bioreactor sizing strategies are optimised, while in the downstream processing (DSP), the 
chromatography sequencing and column sizing strategies, including the resin at each 
chromatography step, the number of columns, the column diameter and bed height, and the number 
of cycles per batch, are determined. Meanwhile, the product’s purity requirement is considered. 
Under the uncertainties of both upstream titre and chromatography resin yields, a stochastic mixed 
integer linear programming (MILP) model is developed, using chance constrained programming 
(CCP) techniques, to minimise the total cost of goods (COG). The model is applied to an 
industrially-relevant example and the impact of different USP:DSP ratios is studied. The 
computational results of the stochastic optimisation model illustrate its advantage over the 
deterministic model. Also, the benefit of the integrated optimisation of both USP and DSP is 
demonstrated. The sensitivity analysis of both the confidence level used in the CCP model and the 
initial impurity level is investigated as well. 
Keywords: biopharmaceutical manufacturing, integrated optimisation, uncertainty, chance 
constrained programming, mixed integer linear programming 
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1. Introduction 
Monoclonal antibodies (mAbs) represent one of the fastest growing groups of therapeutic 
biopharmaceutical drugs. The total global sales revenue of all mAb drugs in 2013 was almost 
US$75 billion, approximately half of the total sales of all biopharmaceutical drugs, and the growth 
of the sales of mAb drugs will continue in the near future
1
. The upstream processing (USP) of 
mAbs manufacturing process is becoming more challenging, due to the significant improvements 
in USP productivities with higher mAb upstream titres being achieved in cell culture. The 
downstream processing (DSP), in which chromatography operations are critical steps representing 
a large proportion of the total manufacturing cost, needs to match the increased titres in the USP
2
. 
Thus, it is critical to identify cost-effective manufacturing processes to overcome manufacturing 
bottlenecks through the optimisation of the design and operation of both upstream fermentation and 
downstream chromatography steps.  
 
Optimisation-based decision-support tools have been developed for the biopharmaceutical 
manufacturing using mathematical programming techniques in the literature, e.g., on the 
biopharmaceutical production planning and scheduling
3-7
, capacity planning
8
, purification process 
synthesis
9-12
. Several optimisation-based approaches have been developed for the optimal design of 
downstream purification processes. A meta-heuristic optimisation approach was developed using 
genetic algorithms, and applied it to a case study on the production of mAbs, focusing on the 
optimal purification sequences and chromatography column sizing strategies, in order to cope with 
different configurations of upstream and downstream trains and product impurity loads
13
. A real-
world problem concerned with the discovery of cost-effective equipment sizing strategies for 
purification processes was addressed, which was formulated as a combinatorial closed-loop 
optimisation problem and solved using evolutionary algorithms (EA)
14-16
. In addition, a mixed 
integer linear programming (MILP) model was developed for the optimal chromatography column 
sizing decisions in the mAb manufacturing, considering an objective of the minimisation of cost of 
goods per gram (COG/g) as the above work, for different facility configurations
17
. Later, the above 
work was extended to a mixed integer nonlinear programming (MINLP) model for the facility 
design with the current titre and facility fit with higher titres
18
. The authors further optimised both 
chromatography sequencing and column sizing decisions using mixed integer linear fractional 
3 
 
programming (MILFP) and Dinkelbach’s algorithm with decision variables as discrete or 
continuous
19,20
. Another work developed a mixed-integer dynamic optimisation model for optimal 
development of bioprocesses, which was solved by a hybrid simulation-optimisation 
decomposition algorithm
21
. These works have focused on optimising DSP but not optimising USP 
and DSP simultaneously, which is one of the objectives of this paper. 
 
In industrial practice, the upstream fermentation titre and downstream chromatography resin yield 
are usually uncertain, which can affect the performance of the whole manufacturing process 
significantly, and should be taken into account in the optimisation model. The chance constrained 
programming (CCP) approach, firstly introduced by Charnes and Cooper
22
, and has been widely 
used in engineering applications to deal with uncertainties
3,23-28
. Under the CCP approach, the 
optimal solution ensures a specified probability of complying with constraints, i.e., the confidence 
level of being feasible. Compared to stochastic programming, the CCP approach usually requires 
much fewer constraints and equations that are similar in number to the deterministic model, and 
has a better performance in terms of ease of solution. This work aims to develop an optimisation 
framework by extending our previous work
17-20
 to address the integrated optimisation of strategies 
for both USP and DSP for the mAb manufacturing, using CCP techniques to deal with the 
uncertainties of the upstream titre and chromatography resin yield. In the USP, the optimal design 
of the upstream facilities is considered by determining the optimal bioreactor volumes with given 
configurations of USP and DSP trains, while in the DSP we consider the optimisation of both the 
chromatography columns sizing and chromatography sequencing strategies. Due to the interactions 
among the manufacturing operations, these strategies should be optimised simultaneously to obtain 
the optimal decisions.    
 
The rest of this paper is organised as follows: Section 2 describes the integrated optimisation 
problem of both USP and DSP design. The mathematical formulation of the proposed stochastic 
integrated optimisation model is presented in Section 3. In Section 4, an industrially-relevant 
example is presented, and its computational results and discussion are given in Section 5. Finally, 
the concluding remarks are made in Section 6.  
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2. Problem Statement 
This work addresses the integrated optimisation of the mAb manufacturing strategies, including the 
bioreactor sizing strategies in the USP, and the column sequencing and sizing strategies in the 
DSP. Fig. 1 shows a typical mAb platform process studied in this work. After mammalian cells 
expressing the mAb are cultured in bioreactors in the USP (see “Cell culture” in Fig. 1), the mAb is 
recovered, purified and cleared from potential viruses by a number of DSP operations, including 
three packed-bed chromatography steps, i.e. capture, intermediate purification and polishing steps. 
These DSP steps operate in a non-overlapping mode, which means when a DSP step is operating, 
other DSP steps are idle. 
 
 
Fig. 1. A typical mAb manufacturing process 
 
Here, the optimal volumes of bioreactors in the USP are considered as decision variables for 
optimisation, rather than pre-determined as in the literature. With given configurations of USP and 
DSP trains, it is assumed that all bioreactors have the same volume, and they operate in the 
staggered pattern.  
 
There are a number of candidate resins from different types to be selected at each chromatography 
step in the DSP for the optimal chromatography sequencing decisions. In order to use the 
orthogonal separation mechanisms, it is assumed that no more than one resin from the same type 
can be used in the sequence. In addition, at each chromatography step, the column sizing strategies 
are to be optimised, including the bed height, diameter, number of cycles and number of columns 
to run in parallel, whose optimal values are to be chosen from a set of discrete candidate values.  
 
In addition, the purity requirement of final product is considered. The host cell proteins (HCPs) are 
considered as the critical impurities, which may cause antigenic effects in patients and must be 
removed during DSP
29
. A target level of the HCPs in the final product specification is to be met by 
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the selected chromatography sequence, where each resin will have a different HCP reduction 
capability.  
 
In this problem, the upstream titre and chromatography step yield with each resin are considered as 
uncertain parameters which follow triangular distributions
14-16,30
. It is assumed that the upstream 
titre and step yields remain the same for different batches. The given annual demand should be met 
by the annual output. In our previous work
17-20
, the optimisation objective was to minimise the 
COG/g, which is equal to the annual total cost divided by the annual total output. However, in this 
problem, as the annual demand is required to be met, i.e. the total output is equal to the demand, 
the minimisation of COG/g is equivalent to the minimisation of the total cost of goods (COG), 
which comprises of both direct and indirect operating costs. 
 
The problem addressed in this work can be described as follows.  
Given: 
 process sequence of a mAb product; 
 a number of USP trains, and upstream titre; 
 candidate chromatography resins at each step, and their key characteristics (e.g. yield, linear 
velocity, buffer usage, dynamic binding capacity, HCP reduction value); 
 key characteristics of non-chromatography steps (e.g. yield, time, buffer usage); 
 cost data (e.g., reference equipment costs, labour wage, resin, buffer and media prices); 
 candidate column diameters and heights, numbers of cycles and columns; 
 initial and target HCP levels; 
 probability distributions of both titre and chromatography step yield; 
determine: 
 bioreactor sizing strategies; 
 chromatography step sequencing strategies (i.e., resin for each step); 
 chromatography column sizing strategies (i.e. column diameter and bed height, number of 
columns per step, and number of cycles per batch) at each chromatography step; 
 product mass and volume, and buffer usage volume; 
 number of total completed batches; 
 annual total processing time; 
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so as to: 
minimise the annual total COG, including both direct and indirect costs. 
 
3. Mathematical Formulation 
In this section, a deterministic MILP model for the optimal USP bioreactor sizing, DSP 
chromatography sequencing and sizing decisions is initially presented. Then, it is extended to a 
stochastic CCP model to deal with uncertainties in upstream titre and chromatography resin yields. 
Both models are developed based on the MILP model for DSP optimisation
19
, which is presented 
in the Supporting Information. The proposed model for the whole biopharmaceutical 
manufacturing process involves an unavoidable complexity with a large number of constraints and 
variables to track the product mass, product volume, buffer volume and processing time of each 
downstream operation, calculate many direct and indirect cost terms, and linearise the nonlinear 
constraints. Only the newly developed equations in this work are presented in this section.  
 
3.1. Deterministic Formulation  
Firstly, a deterministic MILP model was developed using exact linearisation and piecewise 
linearisation techniques to maximise the total COG. The key difference between the proposed 
model and the literature model
19
 lies in modelling the bioreactor size as a variable. Thus, only the 
constraints related to the bioreactor size are presented here. Please refer to the appendix for other 
constraints involved. 
 
3.1.1. Protein Mass 
In each batch, the initial protein mass going out of the upstream processes depends on the titre of 
the product, 𝑡𝑖𝑡𝑟𝑒, and the working volume of bioreactor: 
𝑀0 = 𝑡𝑖𝑡𝑟𝑒 ⋅ 𝛼 ⋅ 𝐵𝑅𝑉        (1) 
where 𝛼 is the working volume ratio, and 𝐵𝑅𝑉 is a variable for single bioreactor volume. 
  
An auxiliary variable, 𝑈𝑀̅̅ ̅̅ ?̅?𝑛 ≡ 𝑈𝑠𝑟 ⋅ 𝑀𝑠−1 , is introduced to calculate the protein mass at 
chromatography step s, 𝑀𝑠, supported by the following constraints:  
𝑈𝑀̅̅ ̅̅ ?̅?−1,𝑟 ≤ 𝑡𝑖𝑡𝑟𝑒 ⋅ 𝛼 ⋅ 𝑚𝑎𝑥𝑏𝑟𝑣 ⋅ 𝑈𝑠𝑟 ,   ∀𝑠 ∈ 𝐶𝑆, 𝑟 ∈ 𝑅𝑠        (2) 
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∑ 𝑈𝑀̅̅ ̅̅ ̅𝑠−1,𝑟𝑟∈𝑅𝑠 = 𝑀𝑠−1,    ∀𝑠 ∈ 𝐶𝑆    (3) 
where 𝑀𝑠 is the product mass per batch after operation s, and binary variable 𝑈𝑠𝑟 is equal to 1 if 
resin r is selected for chromatography step s. 
 
Another auxiliary variable 𝑍𝑀̅̅̅̅̅𝑠𝑛 ≡ 𝑍𝑛 ⋅ 𝑀𝑠 , is introduced for the calculation of annual product 
output, 𝐴𝑃, with the following auxiliary constraints: 
𝑍𝑀̅̅̅̅̅𝑠𝑛 ≤ 𝑡𝑖𝑡𝑟𝑒 ⋅ 𝛼 ⋅ 𝑚𝑎𝑥𝑏𝑟𝑣 ⋅ 𝑍𝑛,   ∀𝑠 = 𝑏𝑓, 𝑛 = 1, … , 𝑞   (4) 
𝑍𝑀̅̅̅̅̅𝑠𝑛 ≤ 𝑀𝑠,   ∀𝑠 = 𝑏𝑓, 𝑛 = 1, … , 𝑞    (5) 
𝑍𝑀̅̅̅̅̅𝑠𝑛 ≥ 𝑀𝑠 − 𝑡𝑖𝑡𝑟𝑒 ⋅ 𝛼 ⋅ 𝑚𝑎𝑥𝑏𝑟𝑣 ⋅ (1 − 𝑍𝑛),   ∀𝑠 = 𝑏𝑓, 𝑛 = 1, … , 𝑞   (6) 
where 𝑍𝑛 is a binary variable to indicate whether if the nth digit of the binary representation of 
variable 𝐵𝑁 is equal to 1. 
 
Different from the literature models
17-20
, the annual product output is required to meet the annual 
demand in this work, to avoid unreasonably large bioreactor size. In this case, more bioreactors 
may result in more batches with smaller batch size, i.e. smaller bioreactor volume. 
𝐴𝑃 = 𝑑𝑒𝑚       (7) 
 
3.1.2.  Product Volume 
For each batch, the initial product volume from the USP, 𝑃𝑉0, is equal to the working volume of 
the bioreactor. 
𝑃𝑉0 = 𝛼 ⋅ 𝐵𝑅𝑉      (8) 
 
3.1.3. Purity 
The purity of the mAb product after the purification processes should meet certain requirements. 
HCPs, which are produced or encoded by the organisms and unrelated to the intended mAb product, 
are considered as the critical impurities in the considered processes. In the USP, the initial level of 
the HCPs, 𝑖𝑛𝑖ℎ𝑐𝑝 (in ng of HCP per mg of mAb product), is known. In the DSP, the ability to 
remove HCPs by each resin is measured in terms of log reduction value (LRV), 𝑙𝑟𝑣𝑠𝑟. The selected 
purification process should be able to reduce the HCP level below a target value, 𝑡𝑎𝑟ℎ𝑐𝑝, in order 
to meet the purity requirement of the final product.  
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𝑖𝑛𝑖ℎ𝑐𝑝
10
∑ ∑ 𝑙𝑟𝑣𝑠𝑟⋅𝑈𝑠𝑟𝑟∈𝑅𝑠𝑠∈𝐶𝑆
≤ 𝑡𝑎𝑟ℎ𝑐𝑝      (9) 
which is equivalent to the following linear constraint by applying the logarithm operation: 
lg 𝑖𝑛𝑖ℎ𝑐𝑝 − ∑ ∑ 𝑙𝑟𝑣𝑠𝑟 ⋅ 𝑈𝑠𝑟𝑟∈𝑅𝑠𝑠∈𝐶𝑆 ≤ lg 𝑡𝑎𝑟ℎ𝑐𝑝    (10) 
 
3.1.4. Costs 
The media cost is determined by the media overfill allowance, 𝜃 , the media price, 𝑚𝑒𝑝𝑐 , the 
bioreactor working volume, 𝛼 ⋅ 𝐵𝑅𝑉, and the number of batches, 𝐵𝑁: 
𝑀𝐸𝐶 = 𝜃 ⋅ 𝑚𝑒𝑝𝑐 ⋅ 𝛼 ⋅ 𝐵𝑅𝑉 ⋅ 𝐵𝑁     (11) 
which is  linearised by introducing 𝑍𝐵𝑅𝑉̅̅ ̅̅ ̅̅ ̅̅𝑛 ≡ 𝑍𝑛 ⋅ 𝐵𝑅𝑉 and the following constraints: 
𝑍𝐵𝑅𝑉̅̅ ̅̅ ̅̅ ̅̅𝑛 ≤ 𝑚𝑎𝑥𝑏𝑟𝑣 ⋅ 𝑍𝑛,   ∀𝑛 = 1, … , 𝑞    (12) 
𝑍𝐵𝑅𝑉̅̅ ̅̅ ̅̅ ̅̅𝑛 ≤ 𝐵𝑅𝑉,   ∀𝑛 = 1, … , 𝑞    (13) 
𝑍𝐵𝑅𝑉̅̅ ̅̅ ̅̅ ̅̅𝑛 ≥ 𝐵𝑅𝑉 − 𝑚𝑎𝑥𝑏𝑟𝑣 ⋅ (1 − 𝑍𝑛),   ∀𝑛 = 1, … , 𝑞     (14) 
 
Thus, we rewrite Eq. (11) as follows: 
𝑀𝐸𝐶 = 𝜃 ⋅ 𝑚𝑒𝑝𝑐 ⋅ 𝛼 ⋅ ∑ 2𝑛−1 ⋅ 𝑍𝐵𝑅𝑉̅̅ ̅̅ ̅̅ ̅̅𝑛
𝑞
𝑛=1     (15) 
 
The utilities cost, 𝑈𝐶, is assumed to have three parts, which are proportional to the total bioreactor 
volume, 𝑏𝑟𝑛 ⋅ 𝐵𝑅𝑉, number of completed batches by single bioreactor volume, 𝐵𝑅𝑉 ⋅ 𝐵𝑁, and 
annual buffer volume, 𝐴𝐵𝑉, respectively.  
𝑈𝐶 = 𝑎 ⋅ 𝑏𝑟𝑛 ⋅ 𝐵𝑅𝑉 + 𝑏 ⋅ 𝐵𝑅𝑉 ⋅ 𝐵𝑁 + 𝑐 ⋅ 𝐴𝐵𝑉    (16) 
where a, b, c are coefficient to calculate the utilities cost. Given Eqs. (12)-(14), the bilinear term 
𝐵𝑅𝑉 ⋅ 𝐵𝑁 can be linearised, and Eq. (16) can be replaced by: 
𝑈𝐶 = 𝑎 ⋅ 𝑏𝑟𝑛 ⋅ 𝐵𝑅𝑉 + 𝑏 ⋅ ∑ 2𝑛−1 ⋅ 𝑍𝐵𝑅𝑉̅̅ ̅̅ ̅̅ ̅̅𝑛
𝑞
𝑛=1 + 𝑐 ⋅ 𝐴𝐵𝑉    (17) 
 
The fixed capital investment consists of the capital investment for bioreactors, chromatography 
columns, as well as other equipment in DSP, whose cost is assumed to be proportional to the 
bioreactor cost. Here, Lang factor, 𝑙𝑎𝑛𝑔, is used to approximate the fixed capital investment31. In 
addition, the general equipment factor, gef, is used to take into account the costs of support 
equipment, spares, utilities equipment and vessels.  
𝐹𝐶𝐼 = 𝑙𝑎𝑛𝑔 ⋅ (1 + 𝑔𝑒𝑓) ⋅ (𝑏𝑟𝑛 ⋅ 𝐵𝑅𝐶 + ∑ ∑ 𝑐𝑐𝑠𝑖 ⋅ 𝐶𝑁𝑠𝑖𝑖𝑠∈𝐶𝑆 + 𝑜𝑒𝜆 ⋅ 𝑏𝑟𝑛 ⋅ 𝐵𝑅𝐶)   (18) 
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where 𝑐𝑐𝑠𝑖 = 𝑟𝑒𝑓𝑐𝑐 ⋅ (
𝑑𝑚𝑠𝑖
𝑟𝑒𝑓𝑑𝑚
)
𝑐𝑓
, in which 𝑟𝑒𝑓𝑐𝑐 is the cost of a chromatography column with a 
reference diameter of 𝑟𝑒𝑓𝑑𝑚, and  𝑐𝑓 is the scale-up factor for chromatography column cost. Also, 
gef refers to the general equipment factor taking into account the costs of support equipment, 
spares, utilities equipment and vessels. 
 
In addition, variable 𝐵𝑅𝐶 in Eq. (18) is the cost of one bioreactor, which is dependent on the 
bioreactor volume. Here, we use piecewise linearisation approximation to calculate 𝐵𝑅𝐶. Given a 
number of discrete bioreactor volumes, 𝑑𝑏𝑟𝑣𝑚, their corresponding bioreactor costs are given by 
𝑑𝑏𝑟𝑐𝑚 = 𝑟𝑒𝑓𝑏𝑟𝑐 ⋅ (
𝑑𝑏𝑟𝑣𝑚
𝑟𝑒𝑓𝑏𝑟𝑣
)
𝑏𝑟𝑓
, where 𝑟𝑒𝑓𝑏𝑟𝑣 is the reference volume of one bioreactor; 𝑟𝑒𝑓𝑏𝑟𝑐 
is the cost of one bioreactor with a volume of 𝑟𝑒𝑓𝑏𝑟𝑣; and 𝑏𝑟𝑓 is the scale-up factor for bioreactor. 
Thus, by introducing a SOS2 variable, Λ𝑚, we have: 
𝐵𝑅𝐶 = ∑ 𝑑𝑏𝑟𝑐𝑚 ⋅ Λ𝑚𝑚        (19) 
𝐵𝑅𝑉 = ∑ 𝑑𝑏𝑟𝑣𝑚 ⋅ Λ𝑚𝑚       (20) 
∑ Λ𝑚𝑚 = 1       (21) 
 
The general utilities cost, 𝐺𝑈𝐶, included in the other indirect costs, depends on the total bioreactor 
volume, i.e., the product of the number of bioreactors and the bioreactor volume. 
𝐺𝑈𝐶 = 𝑔𝑢 ⋅ 𝑏𝑟𝑛 ⋅ 𝐵𝑅𝑉      (22) 
 
3.1.5. Objective Function 
The objective of this optimisation problem is to minimise the total COG, including both direct and 
indirect costs (as defined in Eq. (S.84) in the Supporting Information). 
𝑂𝐵𝐽 = 𝐶𝑂𝐺      (23) 
 
Overall, the optimisation problem is formulated as a deterministic MILP model (denoted as DM) 
with Eqs. (1)-(8), (10), (12)-(15), (17)-(22), as well as Eqs. (S.1)-(S.7), (S.9), (S.10), (S.13), (S.17)-
(S.28), (S.30)-(S.69), (S.71)-(S.75), (S.77), (S.79)-(S.81), (S.83) and (S.84) in the Supporting 
Information, as constraints, and Eq. (23) as the objective function.   
 
3.2. Stochastic Formulation  
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Based on the above deterministic formulation, the uncertain upstream titre and chromatography 
resin yields, which follow a triangular probability distribution, were taken into account for the 
stochastic formulation. The classic CCP approach was used to tackle these uncertainties. In the 
CCP approach, the decision maker firstly expresses a risk tolerance, i.e., a permissible probability 
of violation in the constraints involving uncertain parameters. Expressed by the inverse cumulative 
distribution function, the developed chance constraints are transformed into their deterministic 
equivalent formulations. The details of the new chance constraints under uncertainty in the CCP 
approach are presented in this section.  
 
3.2.1. Chance constraints under uncertain titre 
To develop a chance constraint for the uncertain parameter, titre, the constraint Eq. (1) in the 
previous section, should be firstly converted into an inequality as shown in Eq. (24), as 𝑀0  is 
maximised to satisfy the demand.  
𝑀0 ≤ 𝑡𝑖𝑡𝑟𝑒 ⋅ 𝛼 ⋅ 𝐵𝑅𝑉       (24) 
 
The corresponding chance constraint of Eq. (24) is formulated as follows: 
Pr(𝑀0 ≤ 𝑡𝑖𝑡𝑟𝑒 ⋅ 𝛼 ⋅ 𝐵𝑅𝑉) ≥ 𝐴
𝑡      (25) 
where 𝐴𝑡 is a minimum prespecified probability that Eq. (24) will hold true, greater than 50%. 
 
The above Eq. (25) can be written as follows: 
Pr (𝑡𝑖𝑡𝑟𝑒 ≥
𝑀0
𝛼⋅𝐵𝑅𝑉
) ≥ 𝐴𝑡       (26) 
which is equivalent to 
1 − Pr (𝑡𝑖𝑡𝑟𝑒 ≤
𝑀0
𝛼⋅𝐵𝑅𝑉
) ≥ 𝐴𝑡      (27) 
 
Here, it is assumed that the upstream titre follows a triangular probability distribution, 
Tr(𝑡𝑖𝑡𝑟𝑒𝑙𝑜 , 𝑡𝑖𝑡𝑟𝑒𝑚𝑜 , 𝑡𝑖𝑡𝑟𝑒𝑢𝑝) , where 𝑡𝑖𝑡𝑟𝑒𝑙𝑜  and 𝑡𝑖𝑡𝑟𝑒𝑢𝑝  are lower and upper bounds of the 
fermentation titre, and 𝑡𝑖𝑡𝑟𝑒𝑚𝑜  is the mode. Its cumulative distribution function is denoted as 
Φ(𝑥). Thus, we rewrite Eq. (27) as: 
Φ (
𝑀0
𝛼⋅𝐵𝑅𝑉
) ≤ 1 − 𝐴𝑡      (28) 
Thus, the deterministic equivalent formulation of Eq. (24) is as follows: 
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𝑀0 ≤ Φ
−1(1 − 𝐴𝑡) ⋅ 𝛼 ⋅ 𝐵𝑅𝑉     (29) 
 
For a special case of the isosceles triangular distribution that 𝑡𝑖𝑡𝑟𝑒𝑢𝑝 − 𝑡𝑖𝑡𝑟𝑒𝑚𝑜 = 𝑡𝑖𝑡𝑟𝑒𝑚𝑜 −
𝑡𝑖𝑡𝑟𝑒𝑙𝑜 = ∆𝑡𝑖𝑡𝑟𝑒, when 𝐴𝑡 > 50%, we have: 
Φ−1(1 − 𝐴𝑡) = 𝑡𝑖𝑡𝑟𝑒𝑙𝑜 + √2(1 − 𝐴𝑡) ⋅ ∆𝑡𝑖𝑡𝑟𝑒   (30) 
 
3.2.2. Chance constraints under uncertain yields 
It is assumed that the realisation of uncertain chromatography yield for each resin depends on the 
chromatography step it is selected for. To model the uncertainty of chromatography yield, we 
introduce an uncertain parameter, 𝑐𝑦𝑑𝑠 , to denote the deviation of the selected resin from its 
standard value at chromatography step s. Thus, we can rewrite the constraint involving the resin 
yield, (Eq. S.10 in Supporting Information), as follows: 
𝑀𝑠 = ∑ 𝑐𝑦𝑠𝑟𝑟∈𝑅𝑠 ⋅ 𝑈𝑀
̅̅ ̅̅
?̅?−1,𝑟 ⋅ 𝑐𝑦𝑑𝑠,   ∀𝑠 ∈ 𝐶𝑆     (31) 
 
Similarly, the above constraint is converted into inequality, and its corresponding chance constraint 
can be formulated as: 
Pr(𝑀𝑠 ≤ ∑ 𝑐𝑦𝑠𝑟𝑟∈𝑅𝑠 ⋅ 𝑈𝑀
̅̅ ̅̅
?̅?−1,𝑟 ⋅ 𝑐𝑦𝑑𝑠) ≥ 𝐴𝑠
𝑦,   ∀𝑠 ∈ 𝐶𝑆    (32) 
 
It is assumed that 𝑐𝑦𝑣𝑠  follows a triangular distribution Tr(𝑐𝑦𝑑𝑠
𝑙𝑜 , 𝑐𝑦𝑑𝑠
𝑚𝑜 , 𝑐𝑦𝑑𝑠
𝑢𝑝), in which the 
mode 𝑐𝑦𝑑𝑠
𝑚𝑜 = 100%, 𝑐𝑦𝑑𝑠
𝑙𝑜  and 𝑐𝑦𝑑𝑠
𝑢𝑝
 are lower and upper bounds of the yield deviation at 
chromatography step s, and its cumulative distribution function is denoted as Φ̅𝑠(𝑥). Thus, Eq. (32) 
can be reformulated as: 
Φ̅𝑠 (
𝑀𝑠
∑ 𝑐𝑦𝑠𝑟𝑟∈𝑅𝑠 ⋅𝑈𝑀
̅̅ ̅̅ ̅𝑠−1,𝑟
) ≤ 1 − 𝐴𝑠
𝑦 ,   ∀𝑠 ∈ 𝐶𝑆     (33) 
 
Using the inverse cumulative distribution function expression, we have: 
𝑀𝑠 ≤ Φ̅𝑠
−1(1 − 𝐴𝑠
𝑦) ⋅ ∑ 𝑐𝑦𝑠𝑟𝑟∈𝑅𝑠 ⋅ 𝑈𝑀
̅̅ ̅̅ ̅
𝑠−1,𝑟 ,    ∀𝑠 ∈ 𝐶𝑆   (34) 
 
In particular, if 𝑐𝑦𝑣𝑠 follows an isosceles triangular distribution that 𝑐𝑦𝑑𝑠
𝑢𝑝 − 𝑐𝑦𝑑𝑠
𝑚𝑜 = 𝑐𝑦𝑑𝑠
𝑚𝑜 −
𝑐𝑦𝑑𝑠
𝑙𝑜 = ∆𝑐𝑦𝑑𝑠, when 𝐴𝑠
𝑦 > 50%, we have:   
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Φ̅𝑠
−1(1 − 𝐴𝑠
𝑦) = 𝑐𝑦𝑑𝑠
𝑙𝑜 + √2(1 − 𝐴𝑠
𝑦) ⋅ ∆𝑐𝑦𝑑𝑠,   ∀𝑠 ∈ 𝐶𝑆   (35) 
 
In summary, the deterministic equivalent formulation is an MILP model (denoted as SM) with Eqs. 
(2)-(8), (10), (12)-(15), (17)-(22), (29), (34), as well as Eqs. (S.1)-(S.7), (S.9), (S.13), (S.17)-(S.28), 
(S.30)-(S.69), (S.71)-(S.75), (S.77), (S.79)-(S.81), (S.83) and (S.84) in the Supporting Information, 
as constraints, and Eq. (23) as the objective function.   
 
4. An Illustrative Example 
In this section, an industrially-relevant example is presented, based on a biopharmaceutical 
company using a platform process for mAb purification. The considered mAb product has an 
annual demand of 500 kg. There are 11 candidate commercial resins from five chromatography 
types, including affinity chromatography (AFF), cation-exchange chromatography (CEX), anion-
exchange chromatography (AEX), mixed-mode chromatography (MM) and hydrophobic 
interaction chromatography (HIC). The characteristics of the resin candidates are shown in Table 1. 
Here, each resin/resin type candidate can be suitable for more than one chromatography step, and 
its yield, as well as the HCP reduction capability, varies with the chromatography step where it is 
used. The resin utilisation factor is 0.95, and the resin overpacking factor is 1.1. 
 
Table 1. Characteristics of the candidate resins  
Resin Type Mode 
Binding 
capacity 
(g/L) 
Eluate 
volume 
(CV) 
Buffer 
volume 
(CV) 
Linear 
velocity 
(cm/h) 
Matrix 
lifetime 
(cycle) 
Matrix 
price 
(£/L) 
Standard yield HCP LRV 
Cap. Int. Pol. Cap. Int. Pol. 
R1 AFF BE 50 2.3 37 150 100 9200 91% 95% - 3 1.5 - 
R2 AFF BE 30 2.3 37 300 100 6400 91% 95% - 3 1.5 - 
R3 AFF BE 50 2.3 37 800 100 9900 91% 95% - 3 1.5 - 
R4 AFF BE 30 2.3 37 1000 100 9000 91% 95% - 3 1.5 - 
R5 CEX BE 120 1.4 26 500 100 2500 86% - - 2 - - 
R6 CEX BE 40 1.4 26 300 100 400 86% 92% 92% 2 1 0.5 
R7 AEX FT 100 0 10 300 100 700 - 95% 95% - 0.5 0.3 
R8 MM FT 150 0 10 375 100 3500 - 90% 90% - 1.2 0.6 
R9 MM BE 50 1.4 26 100 100 1900 - 90% 90% - 1.5 0.8 
R10 MM BE 35 1.4 26 250 12 2700 - 90% 90% - 2 1 
R11 HIC BE 27.5 1.4 26 175 100 2500 - 89% 89% - 2 0.5 
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As to the chromatography column sizing decisions, there are 11 discrete potential bed heights and 
10 discrete potential diameters (as given in Table 2), and therefore one column has 110 potential 
volumes. The number of cycles per batch can be up to 10, while at most 4 parallel columns are 
permitted at each chromatography step.  
 
Table 2. Candidate values of the chromatography column sizing strategies  
Decision Candidate values 
Bed height (cm) 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 
Diameter (cm) 50, 60, 70, 80, 90, 100, 120, 160, 180, 200 
Number of cycles 1, 2, 3, 4, 5 , 6, 7, 8, 9, 10  
Number of columns 1, 2, 3, 4 
 
To calculate the fixed capital investment for the bioreactors and chromatography columns, the 
reference equipment sizes, costs, and scale-up factors in Table 3 are used. To approximate the 
bioreactor cost, the bioreactor volumes and costs at given discrete points in the piecewise linear 
function are presented in Table 4.  
 
Table 3. Reference volumes, costs and scale-up factors  
 Reference volume Reference cost (£) Scale-up factor 
Bioreactor Volume = 2000 L 612,000 0.6 
Chromatography column Diameter = 100 cm 170,000 0.8 
 
 
Table 4. Discrete bioreactor volumes and costs for piecewise linear approximation  
m Bioreactor volume, brvm (L) Bioreactor cost, brcm (£) 
1 2,000 612,000 
2 10,000 1,607,500 
3 20,000 2,436,500 
4 50,000 4,222,000 
 
The equipment lifetime, 𝑒𝑙, is 10 years, and the interest rate, 𝑟, is 10%. Here, several cases of 
multiple USP trains feeding one DSP train are investigated, considering four scenarios: 
1USP:1DSP, 2USP:1DSP, 4USP:1DSP and 6USP:1DSP, i.e. 𝑏𝑟𝑛 =1, 2, 4 and 6, respectively. As 
to the HCP levels, the initial value at USP is 100,000 ng/mg, and the target value after DSP is set to 
100 ng/mg. More data of case study are given in the Supporting Information (Tables S1 and S2). 
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The lower and upper bounds of fermentation titre are 2 and 4 g/L, respectively, i.e., the uncertain 
parameter, titre, follows the triangular distribution Tr(2, 3, 4). Also, at each chromatography step, 
the chromatography resin yield can be at most 5% higher or lower than its standard value, which 
means that the yield deviation, 𝑐𝑦𝑑𝑠,  follows the distribution, Tr(95%, 100%, 105%) . The 
unsatisfied demand penalty, γ, is set to £1000/g. 
 
5. Results and Discussion 
The proposed MILP models are implemented in GAMS 24.4
32
 on a 64-bit Windows 7 based 
machine with 3.20 GHz six-core Intel Xeon processor W3670 and 12.0 GB RAM, using CPLEX as 
MILP solver. The optimality gap is set to 1%.  
 
5.1. Optimisation and Monte Carlo Simulation 
In this section, we solve the optimisation models SM and DM, and conduct stochastic analysis to 
examine the impact of variability on their solutions by implementing Monte Carlo (MC) 
simulation
33
.  
 
5.1.1. Optimal Solutions 
To solve model SM, the confidence level of chance constraint feasibility in model SM was set to 
90%, i.e., 𝐴𝑡 = 𝐴𝑠
𝑦 = 90%. Under the given 90% confidence level, Φ−1(1 − 𝐴𝑡) in Eq. (29) is 
approximately equal to 2.45, and Φ̅𝑠
−1(1 − 𝐴𝑠
𝑦) in Eq. (34) is approximately equal to 97.24%, 
according to Eqs. (30) and (35), respectively.  
 
The model statistics and computational performance of model SM in all four scenarios are 
presented in Table 5. Similar to the findings in our previous work
17-20
, the optimal COG increases 
with the number of bioreactors. The computational time spent for solving the problems varies from 
339 to 1613 seconds (s). 
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Table 5. Computational performance of model SM in all scenarios 
 1USP:1DSP 2USP:1DSP 4USP:1DSP 6USP:1DSP 
No of equations 26,940 27,612 28,284 28,284 
No of continuous variables 11,172 11,396 11,620 11,620 
No of discrete variables 28.661 28,662 28,663 28,663 
COG (million £, m£) 43.0 49.1 57.7 66.2 
CPU (s) 339 423 1613 1287 
 
The optimal solutions obtained by model SM are compared with those of model DM, in which the 
mean values of uncertain parameters are used. The key decisions obtained by models SM and DM 
are given in Fig. 2. As the number of cycles per batch are related to the process operation and can 
be determined after the realisation of uncertain parameters, here we focus on the decisions related 
the process design which should be implemented in advance, including bioreactor volume, 
chromatography sequence, and diameter, bed height and number of chromatography columns. In 
each scenario, the gridded cylinder represents the bioreactor. The area of each gridded cylinder is 
proportional to the bioreactor volume, and the number in the gridded cylinder is the single 
bioreactor volume (in L) in the optimal solution. The filled cylinders represent the chromatography 
columns. Here, the number of the filled cylinders represents the number of columns at each 
chromatography step, while its width and height are proportional to the column diameter and bed 
height, respectively. The number in the top area is the column diameter (in cm), and that at the side 
is the column bed height (in cm). Comparing the optimal solutions of both models, to deal with the 
variability of the upstream titre and chromatography resin yields, model SM selects 30% larger 
bioreactor volumes in all scenarios. In the DSP, both models select only one column at each step in 
all scenarios. As to the chromatography sequence, CEX (R5), AEX (R7) and MM (R8) are selected 
in all scenarios, in which CEX (R5) is selected at the capture step in all scenarios by both models. 
The difference among the selected sequences comes from the switch between AEX (R7) and MM 
(R8) at the last two chromatography steps. In scenarios 2USP:1DSP and 6USP:1DSP, models SM 
and DM choose different sequences.  
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Fig. 2. Optimal solutions by models a) SM and b) DM in all scenarios (initial HCP level = 100,000 ng/mg)  
 
5.1.2. MC Simulation  
MC simulation analysis was implemented on the solutions obtained by both models SM and DM. 
After obtaining the optimal solutions of optimisation models DM and SM, an MC simulation 
analysis was conducted by solving a deterministic optimisation model with fixed design variables, 
including variables for bioreactor volume, 𝐵𝑅𝑉, chromatography sequence, 𝑈𝑠𝑟, column volume, 
𝑋𝑠𝑖, and number of columns, 𝐶𝑁𝑠𝑖, while all other operational variables are free to be re-optimised, 
with different realisations of uncertain parameters, 𝑡𝑖𝑡𝑟𝑒 and 𝑐𝑦𝑑𝑠. The performance measures in 
the MC analysis are the average values of COGs and unsatisfied demands obtained in all 
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simulation runs, which mimics the expected value of COG and unsatisfied demand. The procedure 
of MC simulation (as illustrated in Fig. 3) is described as follows: 
1. Solve the proposed MILP model (DM or SM) to minimise COG, and then fix the obtained 
bioreactor volume, chromatography sequence, column volume and the number of columns; 
2. Generate the realisations of uncertain titre and yields, both following triangular probability 
distributions; 
3. Solve the modified MILP model (denoted as DM-USD), which considers unsatisfied demand 
by replacing Eqs. (7) and (23) in model DM by the following Eqs. (36) and (37), respectively:  
𝑈𝑆𝐷 ≥ 𝑑𝑒𝑚 − 𝐴𝑃      (36) 
𝑂𝐵𝐽 = 𝐴𝐶 + 𝛾 ∙ 𝑈𝑆𝐷     (37) 
where the unsatisfied demand, 𝑈𝑆𝐷, is formulated and penalised in the objective function to be 
included in the annual cost, and 𝛾 is the unit penalty cost for unsatisfied demand. 
4. Repeat the above two steps for maxiter times. In this problem, after 200 simulation runs, the 
average objective of all runs has converged to a stable status. Thus, maxiter  is set to 200 here. 
 
Fig. 3. Procedure of MC simulation  
 
Fig. 4 shows the optimal COG by model SM is slightly higher than the average COG obtained in 
the MC simulation, because the chance constraints in model SM slightly overestimate the 
realisation of uncertain parameters. In contrast, the average COG values of the MC simulation 
become much higher than the optimal solutions by model DM, mainly due to the high penalty cost 
of unsatisfied demand. Comparing to model DM, the solutions of model SM obtain smaller average 
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COG values in the MC simulation, with 30-40% difference, and smaller variance, even though 
model SM generates much higher costs in the optimisation. Thus, model SM is much more robust 
than model DM, facing the uncertainties in titre and yields. 
 
 
Fig. 4. COG of the optimisation and MC simulation of models SM and DM in all scenarios. 
 
Focusing on the two extreme scenarios 1USP:1DSP and 6USP:1DSP, the comparison of 
unsatisfied demand in the MC simulation results between the solutions of models DM and SM are 
presented in Fig. 5. The MC simulation of model SM in scenario 1USP:1DSP achieves an annual 
unsatisfied demand of 1.5 kg, while model DM loses over 33.0 kg demand, nearly 7% of the 
annual demand, which is one order of magnitude higher than model SM. In scenario 6USP:1DSP, 
the average unsatisfied demand of MC simulation for model SM is 1.8 kg, which is also one order 
of magnitude lower than that of model DM, 33.0 kg. Thus, it can be observed that the optimal USP 
and DSP designs of model DM cannot cope with the uncertainties very well, and lose more sales 
than the optimal design of model SM, which leads to much higher penalty cost and COG. 
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Meanwhile, the designs of model SM have much better performance and only lose less than 0.5% 
of the annual demand. 
 
Fig. 5. Unsatisfied demand of the MC simulation on the optimal solutions of models SM and DM in scenarios 
1USP:1DSP and 6USP:1DSP 
 
In the MC simulation, the number of cycles per batch is optimised in each run, with fixed design 
variables and given random generations of titre and yields. Thus, we examine its value in the MC 
simulation, as shown in Fig. 6. In scenario 1USP:1DSP, for the solutions of model SM, the latter 
chromatography step requires more cycles, while for model DM, an average of 4-5 cycles are 
needed for each step. In scenario 6USP:1DSP, 1 or 2 cycles are enough at each step for all the MC 
simulation runs, while the solutions of SM require more cycles than those of model DM. 
 
 
Fig. 6. Number of cycles per batch of the MC simulation on the optimal solutions of models SM and DM in scenarios 
1USP:1DSP and 6USP:1DSP 
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The number of batches is also significantly affected by the uncertainties of titre and yield. When 
both titre and yield are higher, fewer batches are required to satisfy the annual demand, while if 
both titre and yield become lower, more batches need to complete with unsatisfied demand 
occurred. The mean and variability of number of batches in the MC simulation are presented in Fig. 
6. In both scenarios, the solution of model SM requires fewer average batches, 16.4 vs 19.2 in 
scenario 1USP:1DSP and 78.4 vs 96.4 in scenario 6USP:1DSP. In scenario 1USP:1DSP, the 
average number of batches of model DM is very close to the maximum value, which is 20, while 
the solution of SM requires fewer batches to satisfy all demands due to the larger bioreactor 
volumes. In scenario 6USP:1DSP, a maximum of 120 batches are available. However, because of 
the higher DSP time than the tight DSP window in scenario 6USP:1DSP, nearly 100 batches are 
finished by model DM, while model SM meets most of the demand using only about 80 batches in 
average. Note that the variability of the solution of model DM is much less than that of model SM. 
The reason is that the solution of model DM is driven to meet the demand by completing all 
possible batches in many MC simulation runs, and has less flexibility to change the completed 
number of batches. Meanwhile, the number of batches required by the solution of model SM is 
affected more significantly by the realised values of uncertain parameters.  
 
Fig. 7. Number of batches of the MC simulation on the optimal solutions of models SM and DM in scenarios 
1USP:1DSP and 6USP:1DSP 
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Overall, the developed CCP based model SM is able to cope with the uncertainties of the 
parameters, upstream titre and downstream resin yields in this problem, achieving lower average 
COG and unsatisfied demand than model DM. 
 
5.1.3. Sensitivity Analysis of Confidence Levels  
The confidence levels used in the chance constraints indicate the probability of the obtained 
solutions being feasible, and have a significant impact on the optimal solutions of the CCP model. 
The example of 1USP:1DSP scenario was taken to investigate the effect of confidence level on the 
performance of the optimal solutions. Without loss of generality, assuming that all chance 
constraints use the same confidence level, we test five different confidence levels, i.e. 80%, 85%, 
90%, 95% and 99%. Table 6 shows the optimal solutions of model SM with the above five 
confidence levels. A higher confidence level, preferred by a risk-averse decision maker, allows the 
chance constraints to remain hold with higher probability. Thus, as shown in Table 6, in order to 
cope with lower titres, the optimal solution of model SM with higher confidence levels select larger 
bioreactor volumes, and incur higher COG and indirect costs. Note that the chromatography 
sequence is affected by the choice of confidence level. Higher conference levels (≥90%) result in 
different chromatography sequences from lower ones (<90%). 
 
Table 6. Optimal solutions of model SM in scenario 1USP:1DSP with different confidence levels 
 
Confidence level 
80% 85% 90% 95% 99% 
COG (m£) 39.8 41.2 43.0 45.6 49.7 
Indirect costs (k£) 15.8 16.1 16.7 17.5 18.8 
Bioreactor volume (L) 28,237 29,557 31,251 33,694 37,452 
Resin R5/R7/R8
a
 R5/R7/R8
a
 R5/R8/R7
a
 R5/R8/R7
a
 R5/R8/R7
a
 
Column diameter (cm) 160/50/50
a
 120/50/50
a
 100/60/60
a
 100/60/60
a
 100/50/50
a
 
Column bed height (cm) 24/24/15
a
 22/25/17
a
 16/15/18
a
 21/21/15
a
 16/19/20
a
 
No. of columns 1/1/1
a
 1/1/1
a
 1/1/1
a
 1/1/1
a
 1/1/1
a
 
    a Capture/intermediate purification/polishing step 
 
The MC simulation results with different confidence levels are shown in Fig. 8. As expected, the 
higher the confidence level is, the lower average unsatisfied demand achieved from MC simulation 
is. The average unsatisfied demand reduces from 5.5 kg to 0.05 kg, with increasing confidence 
levels from 80% to 99%. Meanwhile, comparing the average COG, a higher confidence level 
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requires larger bioreactors and indirect costs, while a lower confidence level incurs higher penalty 
cost due to higher unsatisfied demand. In addition, with increasing higher confidence level, the 
variance of COG in MC simulation decreases. It can be seen from Fig. 8 that the confidence level 
of 90% can achieve a balance between the indirect costs and unsatisfied demand penalty cost, 
obtaining the lowest average COG in MC simulation, and thus is recommended for this problem.  
 
 
Fig. 8. COG and unsatisfied demand of MC simulation on SM solutions in scenario 1USP:1DSP  
 
5.2. Scenario Analysis 
In this section, two specific scenarios are investigated to further discuss the proposed model SM. 
Firstly, the model is compared to an approach with a rule-based pre-determined bioreactor volume 
and an optimisation model with only DSP optimisation, to demonstrate the benefit of integrated 
optimisation of both USP and DSP design. Secondly, the effect of initial HCP level is studied by 
examining a higher initial HCP level. 
 
5.2.1. Pre-determined Bioreactor Volume 
One of the novelties of this work is the integrated optimisation of both USP and DSP design, 
including the bioreactor size at the USP and chromatography decisions at the DSP, which is 
missing in our previous work
17-20
. In this section, we investigate the advantage of the simultaneous 
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integrated optimisation. Firstly, we introduce a rule-based method to estimate the single bioreactor 
volume
12,17,18
, using the formulation as follows:  
𝐵𝑅𝑉 =
𝑑𝑒𝑚
𝛼⋅𝑡𝑖𝑡𝑟𝑒𝑚𝑜⋅𝑚𝑎𝑥𝑏𝑛⋅𝜎⋅∏ min𝑟 𝑐𝑦𝑠𝑟𝑠∈𝐶𝑆 ⋅∏ 𝑛𝑐𝑦𝑠𝑠∉𝐶𝑆
    (38) 
where 𝑑𝑒𝑚 is the annual demand; 𝛼 is the bioreactor working volume ratio; 𝑡𝑖𝑡𝑟𝑒𝑚𝑜 is the mode of 
the titre triangular distribution, which is also its mean value for the case study; 𝑚𝑎𝑥𝑏𝑛 is the 
maximum number of batches allowed; 𝜎 is the batch success rate; 𝑐𝑦𝑠𝑟is the standard value of the 
yield of resin r at chromatography step 𝑠 ∈ 𝐶𝑆, while 𝑛𝑐𝑦𝑠 is the yield of non-chromatography step 
𝑠 ∉ 𝐶𝑆 . Thus, the multiplication of the two product function is an estimation of the overall 
manufacturing yield. The above pre-determined bioreactor volume and its optimal value by model 
SM for our case study are given in Table 7. The estimated bioreactor volume is 20% less than the 
optimal volume in the first three scenarios, while in the last scenario 6USP:1DSP, it is over 30% 
less. 
 
Table 7. Pre-determined and optimal value of single bioreactor volume (L) in all scenarios 
 1USP:1DSP 2USP:1DSP 4USP:1DSP 6USP:1DSP 
Pre-determined bioreactor 
volume by Eq. (38) 
25,016 12,508 6254 4169 
Optimal bioreactor volume by 
model SM 
31,251 15,625 7813 6188 
 
Then, the proposed integrated optimisation (model SM) is compared with the DSP optimisation, in 
which the DSP chromatography strategies are optimised by model SM with variable BRV fixed to 
the pre-determined value obtained by Eq. (38). In order to allow the unsatisfied demand with the 
fixed bioreactor volume, Eqs. (36) and (37) are used to replace Eqs. (7) and (23) in model SM. 
Here, we still take the two extreme scenarios, 1USP:1DSP and 6USP:1DSP, as examples to 
compare the optimal solutions of model SM for DSP optimisation and the integrated optimisation 
of both USP and DSP. The optimal chromatography decisions obtained by DSP optimisation are 
given in Fig. 9. It can be observed that compared with the optimal solution of integrated 
optimisation as decision values in Fig. 2a, different chromatography sequences are selected in both 
scenarios, resulting in different column diameters and bed height as well.  
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Fig. 9. Optimal solution by model SM with pre-determined bioreactor volume in scenarios 1USP:1DSP and 
6USP:1DSP 
 
The MC simulation is conducted on the solutions of both the integrated optimisation and DSP 
optimisation with bioreactor volume pre-determined, as descried in section 5.1.2. The comparison 
on the running average COG and unsatisfied demand obtained in the MC simulation is shown in 
Fig. 10. In scenario 1USP:1DSP, the average unsatisfied demand (9.1 kg) of MC simulation of the 
solution of DSP optimisation is much higher than that of integrated optimisation (1.5 kg), which 
increases the average COG by 17% from £40.2m to £47.1m. While in scenario 6USP:1DSP, the 
advantage of the integrated optimisation is much more significant, as the average unsatisfied 
demand of MC simulation of DSP optimisation is (30.7 kg) is one order of magnitude higher than 
that of the integrated optimisation (1.8 kg). As to the obtained average COG in MC simulation, 
DSP optimisation obtains an average COG of £93.4m, which is over 50% higher than that of the 
integrated optimisation (£61.5m).  
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Fig. 10. Convergence of the average COG and unsatisfied demand of MC simulation on the optimal solutions of 
USP/DSP integrated optimisation and DSP optimisation with bioreactor volume pre-determined by model SM in 
scenarios 1USP:1DSP and 6USP:1DSP 
 
The above comparison demonstrates a clear benefit of the integrated optimisation, which 
synchronises the demand, bioreactor volume and DSP time, and is able to find an optimal solution 
to meet the demand using larger bioreactor volume and fewer batches, while the rule-based method 
for bioreactor volume calculation (Eq. 38) underestimates the bioreactor volume and leads to much 
higher unsatisfied demand, especially when there are more bioreactors and tighter DSP window, 
such as the scenario 6USP:1DSP. Compared to the DSP optimisation with the pre-determined 
bioreactor volumes, the proposed integrated optimisation of both USP and DSP is able to achieve 
much lower unsatisfied demand and COG. Thus, it is important and necessary to consider the 
optimisation of USP bioreactor volumes simultaneously together with the DSP chromatography 
strategies.  
 
Note that if the worst case scenario is considered by replacing the mean by the lower bound of 
uncertain parameters either in the pre-calculation of bioreactor sizes or in the mode DM, the 
unsatisfied demand of both DSP optimisation and model DM in the MC simulation will become 
lower than that of model SM, but the overall COG is still higher than that of model SM. The 
conclusions on the benefits of model SM and the integrated optimisation are still valid. 
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5.2.2. Higher Initial HCP Level  
Lastly, we investigate the effect of the initial HCP level on the optimal solution of SM. We let the 
initial HCP level increase by 15 times to 1,500,000 ng/mg. The optimal solution obtained by model 
SM with this high initial HCP level is given in Fig. 11. Compared with Fig. 2a whose initial HCP 
level is 100,000 ng/mg, a different chromatography sequence is selected, which includes AFF (R3) 
for capture, CEX (R6) for intermediate purification, and AEX (R7) for polishing for all scenarios. 
R3 selected at the capture step is much more expensive than R5 selected with lower initial HCP 
level, and has a higher HCPs reduction ability with a HCP LRV of 3, higher than 2 for R5. 
Although, at the intermediate purification step, R6 is cheaper and has less HCP reduction ability 
than, R8, the total HCP LRV of the optimal sequence in Fig. 11 is 4.3, higher than the sequences in 
Fig. 2a (3.1 for the sequence of R5/R7/R8 or 3.5 for the sequence of R5/R8/R7). So it is clear that 
when the initial HCP level is increased, in order to enforce that the same target HCP level is met, 
the resins with higher HCP reduction abilities are selected, even though they may cost more. In 
addition, as the selected resins in Fig. 11 have higher yields than those in Fig. 2a, which leads to 
less protein loss during processes, the optimal single bioreactor volume becomes smaller for each 
scenario in Fig. 11, but the same annual demand is achieved.  
 
Fig. 11. Optimal solution by model SM in all scenarios (initial HCP level = 1,500,000 ng/mg) 
 
Due to the more expensive price of the selected resins in Fig. 11, especially the resin R3, the direct 
cost for the optimal process with high initial HCP level is higher than that with the low initial HCP 
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level. Meanwhile, as smaller bioreactor volumes are selected with the high initial HCP level in Fig. 
11, lower indirect cost is incurred as shown in Fig. 12. According to the above discussions, the 
initial HCP level has a significant impact on the optimal bioreactor sizing and chromatography 
sequencing decisions. 
 
 
Fig. 12. COG of the optimisation of model SM with low (100,000 ng/mg) and high (1,500,000 ng/mg) initial HCP 
levels, inihcp, in all scenarios. 
 
6. Concluding Remarks 
This paper addressed the integrated optimisation of the both upstream and downstream processing 
of mAb products, considering bioreactor sizing, chromatography sequencing and column sizing 
strategies, simultaneously. The purity requirement of the final product has been taken into account 
as well, to make sure that the final HCP level is below the target. Extended from our previous 
work
17-20
, a stochastic CCP model has been developed, based on a deterministic MILP model, to 
minimise the total COG considering the uncertainties of upstream titre and chromatography resin 
yield. An industrially-relevant example has been investigated for cases with different USP:DSP 
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configurations. The computational results have shown that the stochastic CCP model results in 
larger bioreactor volume and higher indirect cost, but is able to deal with the variability of 
uncertain parameters in a much better manner than the deterministic model, validated by MC 
simulation approach. Also, sensitivity analysis on the confidence level shows its effects on the 
expected cost and unsatisfied demand in the MC simulation. Through scenario analysis, the 
advantage of the integrated optimisation of both USP and DSP decisions is demonstrated through 
MC simulation, achieving lower average COG and unsatisfied demand, compared to the DSP 
optimisation with pre-determined bioreactor volume, which is underestimated by a rule-based 
estimation method. Finally, the initial HCP level is demonstrated to have significant impacts on the 
optimal bioreactor sizing and chromatography sequencing decisions. This work can be extended by  
modelling each batch separately to account for the random realisation of the uncertain parameters 
in each batch, while the proposed stochastic CCP model ignores the variations among batches in 
the real practice. 
 
Supporting Information  
More data of the case study and the literature model
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Nomenclature 
Indices 
i  column size 
m  bioreactor volume 
n  digit of the binary representation 
r  resin 
s  downstream step 
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Sets 
CS  set of chromatography steps, = capture, intermediate purification, polishing 
𝑅𝑠  set of resins suitable to chromatography step s 
 
Parameters 
a, b, c  utilities cost coefficients 
𝐴𝑡     confidence level in chance constraint for initial mass 
𝐴𝑠
𝑦
  confidence level in chance constraint for mass after chromatography step s 
𝑏𝑟𝑓  scale-up factor of bioreactor cost 
𝑏𝑟𝑛  number of bioreactors 
𝑐𝑐𝑠𝑖  column cost of size i at chromatography step s, £ 
𝑐𝑓  scale-up factor of column cost 
𝑐𝑦𝑠𝑟  product yield of resin r at chromatography step s 
𝑐𝑦𝑑𝑠
𝑙𝑜  lower limit of triangular distribution of yield deviation at chromatography step s 
𝑐𝑦𝑑𝑠
𝑚𝑜  mode of triangular distribution of yield deviation at chromatography step s 
𝑐𝑦𝑑𝑠
𝑢𝑝
  upper limit of triangular distribution of yield deviation at chromatography step s 
𝑑𝑏𝑟𝑐𝑚  bioreactor cost at discrete point m, £ 
𝑑𝑏𝑟𝑣𝑚  bioreactor volume at discrete point m, L 
𝑑𝑒𝑚  annual demand, g 
𝑑𝑚𝑠𝑖  diameter of column size i at chromatography step s, L 
𝑔𝑒𝑓  general equipment factor 
𝑔𝑢  general utility unit cost, £/L 
𝑖𝑛𝑖ℎ𝑐𝑝  initial HCP level, ng/mg 
𝑙𝑎𝑛𝑔  Lang factor 
𝑙𝑟𝑣  HCP log reduction value 
𝑚𝑎𝑥𝑏𝑛 maximum number of batches 
𝑚𝑎𝑥𝑏𝑟𝑣 maximum bioreactor volume 
𝑚𝑒𝑝𝑐   media price, £/L 
𝑛𝑐𝑦𝑠  product yield of non-chromatography step s 
𝑜𝑒𝜆  other equipment cost ratio to the bioreactor cost 
𝑞  maximum digit number in the binary representation of number of batches,   
 ⌈log2 𝑚𝑎𝑥𝑏𝑛⌉ 
𝑟𝑒𝑓𝑏𝑟𝑐 reference cost of a bioreactor, £ 
𝑟𝑒𝑓𝑏𝑟𝑣 reference volume of a bioreactor, L 
𝑟𝑒𝑓𝑐𝑐  reference cost of a chromatography column, £ 
𝑟𝑒𝑓𝑑𝑚 reference diameter of a chromatography column, cm 
𝑡𝑎𝑟ℎ𝑐𝑝 target HCP level, ng/mg 
𝑡𝑖𝑡𝑟𝑒  upstream product titre, g/L 
𝑡𝑖𝑡𝑟𝑒𝑙𝑜  lower limit of triangular distribution of upstream product titre, g/L 
𝑡𝑖𝑡𝑟𝑒𝑚𝑜 mode of triangular distribution of upstream product titre, g/L 
𝑡𝑖𝑡𝑟𝑒𝑢𝑝 upper limit of triangular distribution of upstream product titre, g/L 
𝛼  bioreactor working volume ratio 
𝛾  penalty of unsatisfied demand, £/g 
𝜃  media overfill allowance 
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𝜎  batch success rate 
Φ  triangular cumulative distribution function of uncertain titre 
Φ̅𝑠  triangular cumulative distribution function of uncertain resin yield deviation 
 
Continuous Variables 
𝐴𝐵𝑉  annual buffer volume, L 
𝐴𝑃  annual product output, g 
𝐵𝑅𝐶  bioreactor cost, £ 
𝐵𝑅𝑉  single bioreactor volume, L 
𝐶𝑂𝐺  annual cost of goods, £ 
𝐹𝐶𝐼  fixed capital investment, £ 
𝐺𝑈𝐶  general utility cost, £ 
𝑀0  initial product mass entering downstream processes per batch, g 
𝑀𝑠  initial product mass per batch after step s, g 
𝑀𝐸𝐶  media cost, £ 
𝑂𝐵𝐽  objective 
𝑃𝑉0  initial product volume entering downstream processes per batch, L 
𝑈𝐶  utilities cost, £ 
𝑈𝑆𝐷  unsatisfied demand, g 
Λ𝑚  SOS2 variable for piecewise linearization of bioreactor cost  
 
Binary Variables 
𝑈𝑠𝑟  1 if resin r is selected at chromatography step s; 0 otherwise 
𝑋𝑠𝑖  1 if column size i is selected at chromatography step s; 0 otherwise 
𝑍𝑛   1 if the nth digit of the binary representation of variable 𝐵𝑁  is equal to 1; 0 
otherwise 
 
Integer Variables 
𝐵𝑁  number of completed batches 
𝐶𝑁𝑠𝑖  number of columns of size i at chromatography step s 
 
Auxiliary Variables 
𝑈𝑀̅̅ ̅̅ ?̅?−1,𝑟 ≡ 𝑈𝑠𝑟 ⋅ 𝑀𝑠−1 
𝑍𝐵𝑅𝑉̅̅ ̅̅ ̅̅ ̅̅𝑛  ≡ 𝑍𝑛 ⋅ 𝐵𝑅𝑉 
𝑍𝑀̅̅̅̅̅𝑠𝑛  ≡ 𝑍𝑛 ⋅ 𝑀𝑠 
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